UK's Premier Biopartnering & Investment Conference BioTrinity 2011 will bring together investors, global phama and innovative biotech and medtech R&D companies under one roof. Over 75 investment firms are expected to attend this year amongst 750 delegates from over 500 participant companies from 20 countries onboard, making BioTrinity once again the largest gathering of the UK bioindustry. Over 560 delegates from about 400 companies are already confirmed with four weeks to go, with investment firms constituting nearly one fifth of the conference participants (69 firms and rising), and corporate venturers and senior licensing / business development execs from Novartis, AstraZeneca, Roche, Shire, Merck, GSK, Sanofi Aventis, Pfizer, Boehringer, Baxter, Takeda, Teva, Lilly, Smith & Nephew, Fosun Pharma, Ironwood, Merck Serono, Abbott, Novo A/S, J&J and Lundbeckfund already confirmed for 2011 maintaining BioTrinity again as an ever-expanding well organized and unique offering of valuable investor and pharma partnering opportunities.
PYC Price at posting:
6.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)